
iVexSol is excited to support innovation in CGT with our new Packaging Cell Line Early Access Program. Here’s how it works, and how you can enroll today.
Select the appropriate stage below to see how iVexSol’s Intelligent Manufacturing can provide time-saving and cost-effective solutions to enable your clinical development program
iVexSol’s Intelligent Manufacturing solutions are highly scalable and designed to support you through clinical development and beyond.
We are working to eliminate human disease by developing transformative vector production technologies for cell and gene therapies
iVexSol is excited to support innovation in CGT with our new Packaging Cell Line Early Access Program. Here’s how it works, and how you can enroll today.
Expanded role will help accelerate access to stable producer cell line technology, helping to solve lentiviral vector shortages for CGT
Expanded board to enable iVexSol to advance growth strategy and address lentiviral vector shortage for CGT
Kenneth Locke and Ian Smith, industry leaders in Cell and Gene Therapy, join as iVexSol advisors
Funds will be used to invest in iVexSol's next-generation lentiviral vector production platform
Viral vector manufacturing and transduction processes today are lengthy and inconsistent
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.
A gateway to explore a next generation stable lentiviral vector manufacturing technology
FOR IMMEDIATE RELEASE
Technology targets critical shortage of viral vectors for the rapidly
expanding field of cell and gene therapeutics
iVexSol is excited to support innovation in CGT with our new Packaging Cell Line Early Access Program. Here’s how it works, and how you can enroll today.
Expanded role will help accelerate access to stable producer cell line technology, helping to solve lentiviral vector shortages for CGT
Expanded board to enable iVexSol to advance growth strategy and address lentiviral vector shortage for CGT
Kenneth Locke and Ian Smith, industry leaders in Cell and Gene Therapy, join as iVexSol advisors
Funds will be used to invest in iVexSol's next-generation lentiviral vector production platform
Viral vector manufacturing and transduction processes today are lengthy and inconsistent
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.
A gateway to explore a next generation stable lentiviral vector manufacturing technology
FOR IMMEDIATE RELEASE
Technology targets critical shortage of viral vectors for the rapidly
expanding field of cell and gene therapeutics